Archive | 2021
Preliminary Study on The Relationship of BRAF Mutations to The Outcome of The First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma
Abstract
\n Objective To investigate the relationship of BRAF mutation to the outcome of the first postoperative 131I treatment and malignant biological characteristics in papillary thyroid carcinoma (PTC) and the clinical value of circulating tumor DNA (ctDNA). Methods Thirty-three patients with PTC underwent the first 131I treatment after total thyroidectomy were enrolled in this study. BRAF mutation based on postoperative tumor tissue and ctDNA in peripheral blood before 131I treatment were detected. According to the status of BRAF mutation, all patients were divided into 2 groups for the categories of tumor tissues and ctDNA respectively: i) BRAF mutated, ii) BRAF wild-type. The Fisher s exact test was performed to analyze the relationship of BRAF mutation in either tumor tissue or ctDNA to the outcome of the first 131I treatment and malignant characteristics of PTC. Results BRAF mutation was detected in 25 patients based on tumor tissue (25/33,75.8%), and all the patients had single mutation site. In ctDNA, BRAF mutation was detected in 5 patients (5/33, 15.2%), and all the patients had single mutation site. BRAF mutation showed no relationship with the outcome of the first 131I treatment and the malignant biological characteristics in both tumor tissues and ctDNA(P>0.05). Conclusion The value of BRAF mutation alone might be limited in predicting therapeutic outcome of the first 131I treatment in PTC. No certain relevance was found between BRAF mutation and malignant biological features in PTC.